Cholesterol feeding accentuates the cyclosporine-induced elevation of renal plasminogen activator inhibitor type 1.

[1]  W. Bennett,et al.  Chronic cyclosporine nephrotoxicity , 1998, Current opinion in nephrology and hypertension.

[2]  A. Eddy.  Interstitial inflammation and fibrosis in rats with diet-induced hypercholesterolemia. , 1996, Kidney international.

[3]  A. Eddy.  Expression of genes that promote renal interstitial fibrosis in rats with proteinuria. , 1996, Kidney international. Supplement.

[4]  W. Bennett,et al.  Role of transforming growth factor-beta 1 in experimental chronic cyclosporine nephropathy. , 1996, Kidney international.

[5]  L. V. Van Gaal,et al.  Elevated plasminogen activator inhibitor levels in cyclosporin-treated renal allograft recipients. , 1996, Nephrology, Dialysis and Transplantation.

[6]  P. Declerck,et al.  Characterization of common neoantigenic epitopes generated in plasminogen activator inhibitor‐1 after cleavage of the reactive center loop or after complex formation with various serine proteinases , 1995, FEBS letters.

[7]  M. Bally,et al.  LIPOSOMAL CYCLOSPORINE: COMPARISON OF DRUG AND LIPID CARRIER PHARMACOKINETICS AND BIODISTRIBUTION , 1995, Transplantation.

[8]  J. Barnes,et al.  Expression of plasminogen activator-inhibitor-1 (PAI-1) during cellular remodeling in proliferative glomerulonephritis in the rat. , 1995, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[9]  C. Alpers,et al.  Cellular proliferation and macrophage influx precede interstitial fibrosis in cyclosporine nephrotoxicity. , 1995, Kidney international.

[10]  M. Robertson,et al.  Oxidation of low density lipoproteins from patients with renal failure or renal transplants. , 1995, Kidney international.

[11]  A. Eddy,et al.  Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. , 1995, Kidney international.

[12]  T. Hammond,et al.  Segmental distribution of the endocytosis receptor gp330 in renal proximal tubules. , 1995, European journal of cell biology.

[13]  J. Horton,et al.  Regulation of Hepatic 7α-Hydroxylase Expression and Response to Dietary Cholesterol in the Rat and Hamster (*) , 1995, The Journal of Biological Chemistry.

[14]  R. Chalmers,et al.  Effect of low-dose cyclosporin on plasma lipoproteins and markers of cholestasis in patients with psoriasis. , 1995, QJM : monthly journal of the Association of Physicians.

[15]  R. Atkins,et al.  A novel, simple, reliable, and sensitive method for multiple immunoenzyme staining: use of microwave oven heating to block antibody crossreactivity and retrieve antigens. , 1995, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[16]  D. Sgoutas,et al.  CYCLOSPORINE INCREASES THE OXIDIZABILITY OF LOW‐DENSITY LIPOPROTEINS IN RENAL TRANSPLANT RECIPIENTS , 1994, Transplantation.

[17]  K. Rentsch,et al.  Relation of cyclosporine blood levels to adverse effects on lipoproteins. , 1994, Transplantation.

[18]  E. Emeson,et al.  Accelerated atherosclerosis in hyperlipidemic C57BL/6 mice treated with cyclosporin A. , 1993, The American journal of pathology.

[19]  E. Vilella,et al.  Low-density lipoprotein metabolism in rats treated with cyclosporine. , 1993, Metabolism: clinical and experimental.

[20]  Yufei Wang,et al.  Expression and localization of plasminogen activator inhibitor 1 mRNA in transplant kidneys , 1993, The Journal of pathology.

[21]  E. Tremoli,et al.  Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. An LDL receptor-independent phenomenon. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[22]  D. Steinberg,et al.  Role of oxidized low density lipoprotein in atherogenesis. , 1991, The Journal of clinical investigation.

[23]  Y. Eguchi,et al.  Cellular localization of type 1 plasminogen activator inhibitor messenger RNA and protein in murine renal tissue. , 1993, The American journal of pathology.

[24]  W. Border,et al.  Glomerular matrix accumulation is linked to inhibition of the plasmin protease system. , 1992, Kidney international.

[25]  H. Büller,et al.  IMPAIRED FIBRINOLYSIS IN CYCLOSPORINE‐TREATED RENAL TRANSPLANT PATIENTS ANALYSIS OF THE DEFECT AND BENEFICIAL EFFECT OF FISH‐OIL , 1992, Transplantation.

[26]  S. Moestrup,et al.  Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. , 1992, The Journal of biological chemistry.

[27]  R. Wood,et al.  Proliferating cell nuclear antigen is required for DNA excision repair , 1992, Cell.

[28]  K. Okada,et al.  Tissue‐type plasminogen activator and its inhibitor in human glomerulonephritis , 1992, The Journal of pathology.

[29]  M. Seed,et al.  Lipid and lipoprotein (a) concentrations in renal ransplant patients , 1992 .

[30]  M. Scully.  PLASMINOGEN ACTIVATOR‐DEPENDENT PERICELLULAR PROTEOLYSIS , 1991, British journal of haematology.

[31]  D. Belin,et al.  The plasminogen activator/plasmin system. , 1991, The Journal of clinical investigation.

[32]  B. Lacour,et al.  Atherosclerosis and lipid disorders after renal transplantation. , 1991, Kidney international. Supplement.

[33]  P. Hylemon,et al.  Regulation of bile acid synthesis , 1991, Hepatology.

[34]  K. Preissner,et al.  Structure and biological role of vitronectin. , 1991, Annual review of cell biology.

[35]  V. Kliem,et al.  Impact of long-term immunosuppression with cyclosporin A on serum lipids in stable renal transplant recipients , 1991, Transplant international : official journal of the European Society for Organ Transplantation.

[36]  E. Kovacs.  Fibrogenic cytokines: the role of immune mediators in the development of scar tissue. , 1991, Immunology today.

[37]  H. Aynedjian,et al.  Renal vasoconstriction caused by short-term cholesterol feeding is corrected by thromboxane antagonist or probucol. , 1990, The Journal of clinical investigation.

[38]  A. Hamsten,et al.  Secretion of plasminogen activator inhibitor-1 from cultured human umbilical vein endothelial cells is induced by very low density lipoprotein. , 1990, Arteriosclerosis.

[39]  P. Klotman,et al.  Cellular and molecular mechanisms of cyclosporin nephrotoxicity. , 1990, Journal of the American Society of Nephrology : JASN.

[40]  E. Kruithof,et al.  Plasminogen activator inhibitor 1 in renal fibrin deposits of human nephropathies. , 1990, Clinical nephrology.

[41]  M. Brezis,et al.  Chronic cyclosporine-induced nephropathy in the rat. A medullary ray and inner stripe injury. , 1990, Transplantation.

[42]  A. Gotto,et al.  Effects of cyclosporine therapy on plasma lipoprotein levels. , 1989, JAMA.

[43]  Rochelle L. Garcia,et al.  Analysis of proliferative grade using anti-PCNA/cyclin monoclonal antibodies in fixed, embedded tissues. Comparison with flow cytometric analysis. , 1989, The American journal of pathology.

[44]  L. Truong,et al.  CHRONIC CYCLOSPORINE NEPHROTOXICITY A RODENT MODEL , 1988, Transplantation.

[45]  H. Starklint,et al.  Cyclosporine A in high dosages induces renal interstitial fibrosis in the rat. , 1988, Transplantation proceedings.

[46]  J. Mann,et al.  Adverse effect of cyclosporin on plasma cholesterol in renal transplant recipients. , 1988, Nephrology, Dialysis and Transplantation.

[47]  M. Alessi,et al.  Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. , 1988, Blood.

[48]  C. Hsu,et al.  Alterations in renal structure and function in a rat model of cyclosporine nephrotoxicity. , 1987, The Journal of pharmacology and experimental therapeutics.

[49]  R. Lebo,et al.  cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. , 1986, The Journal of clinical investigation.

[50]  L. Racusen,et al.  Acute renal failure produced by combining cyclosporine and brief renal ischemia in the Munich Wistar rat. , 1986, Clinical nephrology.

[51]  W. Bennett,et al.  Action and toxicity of cyclosporine. , 1986, Annual review of medicine.

[52]  F. Roels,et al.  Cyclosporine nephrotoxicity: comparative cytochemical study of rat kidney and human allograft biopsies. , 1986, Clinical nephrology.

[53]  D. Loskutoff,et al.  Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. , 1985, The Journal of biological chemistry.

[54]  E. Döpp,et al.  The heterogeneity of mononuclear phagocytes in lymphoid organs: distinct macrophage subpopulations in rat recognized by monoclonal antibodies ED1, ED2 and ED3. , 1985, Advances in experimental medicine and biology.

[55]  A. Barclay,et al.  Molecular and antigenic heterogeneity of the rat leukocyte‐common antigen from thymocytes and T and B lymphocytes , 1985, European journal of immunology.

[56]  H. Wilczek,et al.  INTERSTITIAL FIBROSIS IN RENAL ALLOGRAFTS AFTER 12 TO 46 MONTHS OF CYCLOSPORIN TREATMENT: BENEFICIAL EFFECT OF LOW DOSES IN EARLY POST-TRANSPLANTATION PERIOD , 1984, The Lancet.

[57]  A. Smith,et al.  The effect of salt intake on cyclosporine-induced impairment of renal function in rats. , 1984, Transplantation.

[58]  B. Myers,et al.  Cyclosporine-associated chronic nephropathy. , 1984, The New England journal of medicine.

[59]  A. Thomson,et al.  Enhancement of high dose cyclosporin A toxicity by frusemide. , 1984, Biochemical pharmacology.

[60]  W. McMaster,et al.  Two subsets of rat T lymphocytes defined with monoclonal antibodies , 1980, European journal of immunology.

[61]  W. McMaster,et al.  Identification of Ia glycoproteins in rat thymus and purification from rat spleen , 1979, European journal of immunology.